Search Results - apoptosis

13 Results Sort By:
Synthetic Lethality of IR with ABBV-155 in Glioblastoma (GBM) (UCLA Case No. 2021-232)
UCLA researchers in the Department of Molecular and Medical Pharmacology have discovered that irradiation therapy can be combined with an antibody drug conjugate to form a novel therapeutic strategy to treat and extend survival of glioblastoma patients. BACKGROUND: Glioblastoma (GBM) is a fast-growing and aggressive brain tumor. The National Brain...
Published: 8/28/2024   |   Inventor(s): David Nathanson
Keywords(s): Antibody-Drug Conjugate, Apoptosis, Brain cancer, Cancer, Glioblastoma, irradiation
Category(s): Therapeutics > Oncology
Strategies to Detect, Prevent and Reverse Acquired Resistance to Immune Checkpoint Blockade Therapy (UCLA Case No. 2024-085)
UCLA researchers in the Department of Medicine have uncovered novel mechanism of acquired resistance against immune checkpoint blockade therapy in melanoma patients. BACKGROUND: Immune checkpoint blockade (ICB) therapy is a type of cancer immunotherapy that targets immune system components in order to reactivate immune cells to combat tumor cells....
Published: 5/8/2024   |   Inventor(s): Roger Lo
Keywords(s): acquired resistance, Apoptosis, Cancer, Cancer Immunotherapy, Immune checkpoint blockade, Immunotherapy, Melanoma, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Targeting the Intrinsic Apoptotic Machinery in Glioblastoma Multiforme (GBM) (UCLA Case No. 2020-446)
UCLA researchers in the Department of Molecular and Medical Pharmacology identified the mechanisms of apoptotic resistance in glioblastoma multiforme (GBM) and developed a novel therapy to treat GBM. BACKGROUND: Glioblastoma (GBM) is the most aggressive form of brain tumor. Therapeutic options for GBM are limited and suboptimal. Treatment usually...
Published: 2/16/2024   |   Inventor(s): David Nathanson
Keywords(s): anti-apoptotic inhibitor, Anti-apoptotic pathway, Apoptosis, Brain Tumor, Glioblastoma, irradiation, p53, temozolomide
Category(s): Therapeutics > Oncology
Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells
Abstract: The tumor-suppressor p53 protein plays a major role in tumor development. Most human cancers fail to normally activate wild-type p53, which is at least partly responsible for the unregulated growth of cancer cells and their failure to undergo apoptosis. While many chemotherapeutics enhance p53 levels, their non-specific DNA damage (genotoxicity)...
Published: 4/8/2024   |   Inventor(s): Allan Weissman, Yili Yang
Keywords(s): APOPTOSIS, CANCER, HDM2 Inhibitor, p53 Activation, Weissman
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration
Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy
Abstract: Many known chemotherapeutic drugs kill abnormal cells through a process called apoptosis. Bcl-2 proteins are negative regulators of apoptosis that control cell survival and death. Increased expression of anti-apoptotic Bcl-2 proteins commonly occurs in up to 30% of all cancers, providing cancer cells a pro-survival advantage to evade cell...
Published: 4/8/2024   |   Inventor(s): Apurva Srivastava, Dominic Esposito, Jeevan Govindharajulu, Ralph Parchment, James Doroshow
Keywords(s): APOPTOSIS, BCL-2, IMMUNOASSAY, Pharmacodynamic Biomarkers, Pro-Apoptotic, prognostic, Srivastava
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease
Biomarker for Predicting Taxane Chemotherapy Outcome
Abstract: Over the past decades, taxanes such as paclitaxel and docetaxel have emerged as effective chemotherapy agents for breast cancer and other malignancies. Taxanes are effective in many patients, however, not all patients benefit from this type of chemotherapy. A significant need remains for a means of predicting clinical outcome from taxane-based...
Published: 4/8/2024   |   Inventor(s): Sherry Yang, Sandra Swain
Keywords(s): APOPTOSIS, Biomarkers, Docetaxel, Immunohistochemistry, PACLITAXEL, pAkt, taxane
Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Oncology
Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis
Abstract: The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) protein has been a target of interest in cancer therapy because it plays a large role in inducing cell apoptosis in cancer cells but not in normal cells.  Although TRAIL has been reported to successfully target certain tumor cells which are resistant to traditional chemotherapy...
Published: 5/22/2024   |   Inventor(s): Thomas Sayers, Alan Brooks, Curtis Henrich, Poonam Tewary, James McMahon, Leslie Gunatilaka, Yaming Xu, Kithsiri Wijeratne
Keywords(s): APOPTOSIS, Immunotherapy, TLR3 ligands, TRAIL, withanolide
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration
The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof
Abstract: Cancer is the second leading cause of death worldwide. The primary cause of mortality from cancer is metastasis. While the underlying mechanisms of cancer metastasis are still being unraveled, the gp78 protein involved in ER-associated degradation (ERAD) appears to play a role in metastasis in sarcoma. Targeting gp78 may be a therapeutic option...
Published: 4/8/2024   |   Inventor(s): Allan Weissman, Jennifer Mariano, Bo Chen, Yien-Che Tsai
Keywords(s): APOPTOSIS, CANCER, Endoplasmic Reticulum, er, ERAD, ER-associated Degradation, Gp78, Metastasis, STRESS, Ube2G2, Ubiquitin, Weissman
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Collaboration
Methods of Treating Cancer and Ischemia Diseases by Inhibition and Intervention of ATR Prolyl Isomerization
Project ID: D2021-42 Background Cell death and immortality are closely associated with cancer and cancer therapeutics, as oncogenesis requires a compromise of apoptosis while most cancer therapies depend on apoptopsis. Precise regulation of programmed cell death (apoptosis) is essential for cellular and organ homeostasis. Hyperactive apoptosis is...
Published: 5/9/2024   |   Inventor(s): Yue Zou
Keywords(s): Antiapoptotic ATR, Apoptosis, Cancer, Cis and trans, Cytoplasmic ATR, Pin1, Prolyl isomerization
Category(s): Oncology
Cyclin C and its role in cancer and cancer therapeutics
Cancer is a leading cause of death worldwide with more than 14 million new patients diagnosed and almost 9 million deaths every year. Despite increasing survival rates over the past few decades, current treatments such as radiation, chemotherapy, targeted therapies and new immunotherapies still fail in large subsets of patients. Mounting drug resistance...
Published: 3/13/2024   |   Inventor(s): Randy Strich, Katrina Cooper
Keywords(s): Apoptosis, Cancer, Chemotherapy, Cyclin C, Radiation, Synergy, Therapeutic
Category(s): Human Health Care > Therapeutics
1 2